Leronlimab
Leronlimab Uses, Dosage, Side Effects, Food Interaction and all others data.
Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.
Leronlimab is a humanized monoclonal antibody that binds CCR5 being investigated for it's anti-HIV, immunomodulatory, and anti-cancer effects.
| Trade Name | Leronlimab |
| Generic | Leronlimab |
| Leronlimab Other Names | Leronlimab |
| Type | |
| Protein binding | Data regarding the protein binding of leronlimab is not readily available. |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Leronlimab is a humanized monoclonal antibody being investigated
Leronlimab is currently being investigated for the treatment of a number of cancers and HIV.
Recently leronlimab has begun a phase II clinical trial in severely ill COVID-19 patients. Preliminary data shows a reduction in the 'cytokine storm', particularly IL-6, as well as a normalization of the CD4/CD8 T-cell ratio. These results may mitigate immune mediate injury seen in severely ill COVID-19 patients.
How Leronlimab works
CCR5 is a helical protein with multiple extracellular regions with adjacent G proteins. When a chemokine binds CCR5, the Gαβγ trimer phosphorylates GDP to GTP and Gα dissociates. Activated Gα activates adenylate cyclase, and increasing levels of cyclic AMP activate cytosolic protein kinase A. Further downstream effects of CCR5 signalling include activation of NF-κB and IL-6, as well as effects on cell proliferation, migration, and survival.
HIV enters cells expressing CD4 and a fusion coreceptor such as CCR5 and CXCR4. Leronlimab is a monoclonal antibody which binds to multiple extracellular regions of the CCR5 receptor, preventing the entry of HIV into the cell.
Leronlimab's blocking of CCR5 is being investigated in cancer treatment, for it's effect on the cell cycle and immuno-modulation.
Leronlimab is also being investigated as a treatment for patients severely ill with COVID-19 due to it's effects on mitigating the cytokine storm and preventing immune-mediated injury.
Toxicity
Data regarding overdose of leronlimab is not readily available.
Food Interaction
No interactions found.Volume of Distribution
Data regarding the volume of distribution of leronlimab is not readily available.
Elimination Route
A 162mg subcutaneous dose reaches a Cmax of 6.1mg/L, with a Tmax of 32 hours, and an AUC of 24.4mg*day/L. A 324mg subcutaneous dose reaches a Cmax of 13.8mg/L, with a Tmax of 56 hours, and an AUC of 58.8mg*day/L.
Half Life
The half life of a 162mg subcutaneous dose is 3.4 days while the half life of a 324mg subcutaneous dose is 3.7 days.
Clearance
Data regarding the clearance of leronlimab is not readily available.
Elimination Route
Data regarding the route of elimination of leronlimab is not readily available.
Innovators Monograph
You find simplified version here Leronlimab
